The Cardiovascular Effects of GLP‐1 Receptor Agonists
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
SUMMARY: Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists have been shown to regulate blood glucose concentrations by mechanisms including enhanced insulin synthesis/secretion, suppressed glucagon secretion, slowed gastric emptying, and enhanced satiety. GLP‐1 receptors have also been identified in the heart, kidneys, and blood vessels, leading to the hypothesis that GLP‐1R agonists may affect cardiovascular function or cardiovascular disease (CVD). The aim of this literature review was to assemble and assess preclinical and clinical data of potential medical importance regarding the cardiovascular effects of GLP‐1R agonists. Preclinical studies with the GLP‐1R agonists GLP‐1, exenatide, or liraglutide provided evidence that GLP‐1R stimulation favorably affects endothelial function, sodium excretion, recovery from ischemic injury, and myocardial function in animals. Similar observations have been made in exploratory studies on GLP‐1 infusion in normal subjects and patients with type 2 diabetes. Post hoc analyses of phase III studies of patients with type 2 diabetes treated with exenatide(bid or qw) or liraglutide(qd) showed that these GLP‐1R agonists reduced blood pressure, an effect largely independent of weight loss, and that liraglutide slightly increased heart rate. Preliminary data also indicated that GLP‐1R agonists reduced markers of CVD risk such as C‐reactive protein and plasminogen activator inhibitor‐1. Ongoing studies are examining the effects of administering GLP‐1R agonists to patients at risk of CVD, postangioplasty patients, post‐CABG patients, and patients with heart failure. Additional studies should provide meaningful data to determine whether GLP‐1R agonists provide unique treatment benefits to patients at risk for or with established CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“3 kg, but not in a 26-week study of exenatide bid versus liraglutide qd (n = ∼230 per group) in which patients lost ∼3 kg [49,67].”
BackgroundKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 5×
“The metabolites of liraglutide differ from those of exenatide due to liraglutide’s susceptibility to cleavage by DPP-4.”
BackgroundInfluentialBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 6×
“(C) Immunohistochemical staining (green) demonstrating localization of GLP-1R in the endocardium (B, C reproduced with permission from [22]).”
BackgroundMethodInfluentialPrimary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Diabetes Care · doi:10.2337/dc07-9917 · Cited by 1,055
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 2×
“three in the control group) were also observed [57].”
Background
Cited by
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Skov, J., Dejgaard, A., Frøkiær, J., Holst, J. J., Jonassen, T., Rittig, S., & Christiansen, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3855 · Cited by 228
“Other acute studies (23), as well as long term studies with GLP-1 based therapies (27), have shown small but permanent increases in heart rate.”
BackgroundGLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Rizzo, M., Nikolic, D., Patti, A. M., Mannina, C., Montalto, G., McAdams, B. S., Rizvi, A. A., & Cosentino, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.012 · Cited by 152
Younce, C. W., Burmeister, M. A., & Ayala, J. E. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00248.2012 · Cited by 134
The benefits of GLP1 receptors in cardiovascular diseases
Ferhatbegović, L., Mršić, D., & Macić-Džanković, A. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1293926 · Cited by 127
“As well as endogenous GLP-1,GLP-1 receptor agonists also have numerous other effects such as promoting weight loss, deceleration of gastric emptying, lowering blood pressure (systolic and diastolic), and lowering total cholesterol (10, 27 – 29).”
Background
Metadata
- Authors
- Okerson, T., & Chilton, R. J.
- Venue
- Cardiovascular Therapeutics
- Publisher
- Wiley
- Published
- 2010-12-19
- Volume
- 30
- Issue
- 3
- Pages
- e146-55
- ISSN
- 1755-5914 (ISSN-L)
- 1755-5922
- OpenAlex
- W1526784932
- Cited by
- 136
- References
- 25
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Cardiovascular Effects of GLP‐1 Receptor Agonists. https://app.cochat.ai/papers/10.1111/j.1755-5922.2010.00256.x
- The paper
- Okerson, T., & Chilton, R. J. (2012). The Cardiovascular Effects of GLP‐1 Receptor Agonists. Cardiovascular Therapeutics. https://doi.org/10.1111/j.1755-5922.2010.00256.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.